Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

p53 binds to cisplatin-damaged DNA.

C C Wetzel¹, S J Berberich

¹Wright State University, Department of Biochemistry and Molecular Biology, 3640 Colonel Glenn Hyw, Dayton, OH 45435, USA.

Biochimica Et Biophysica Acta

|May 9, 2001

Summary

The tumor suppressor protein p53 binds to DNA damaged by cisplatin, independent of its usual DNA binding sites. This interaction involves specific p53 domains and is stronger than binding to undamaged DNA.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model.

Oncogene·2013

Same author

Full-length hdmX transcripts decrease following genotoxic stress.

Oncogene·2008

Same author

Human NM23/nucleoside diphosphate kinase regulates gene expression through DNA binding to nuclease-hypersensitive transcriptional elements.

Journal of bioenergetics and biomembranes·2002

Same author

Regulation of p63 function by Mdm2 and MdmX.

DNA and cell biology·2001

Same author

MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation.

The Journal of biological chemistry·2001

Same author

MdmX protects p53 from Mdm2-mediated degradation.

Molecular and cellular biology·2000

Area of Science:

Molecular Biology
Cancer Research
Biochemistry

Background:

The p53 protein is a crucial tumor suppressor involved in DNA repair and cell cycle control.
Previous studies demonstrated p53 binding to DNA damaged by cisplatin, even without specific binding sites.
The precise mechanisms and domains of p53 involved in this interaction remained unclear.

Purpose of the Study:

To investigate the specific domains of p53 protein responsible for binding to cisplatin-damaged DNA.
To characterize the binding affinity of p53 to platinated DNA compared to undamaged DNA.
To elucidate the role of p53's DNA-binding and C-terminal domains in interacting with damaged DNA.

Main Methods:

Utilized various p53 mutants to assess the impact of domain-specific alterations on DNA binding.
Performed competition experiments to compare p53 binding preferences between platinated and sequence-specific DNA.
Employed an antibody (pAb421) targeting the C-terminal domain to evaluate its effect on p53-DNA interactions.

Main Results:

Mutations in p53's central core domain abolished binding to platinated DNA.
p53 demonstrated a preference for sequence-specific DNA over platinated DNA in competition assays.
Binding of p53 to cisplatin-damaged DNA was significantly stronger than to undamaged DNA lacking a consensus site.
An antibody targeting the C-terminal domain inhibited p53 binding to platinated DNA.

Conclusions:

Two distinct domains of the p53 protein are critical for its interaction with cisplatin-damaged DNA.
p53 exhibits a dual mode of DNA interaction, binding to both specific sites and damaged DNA structures.
These findings suggest a broader role for p53 in recognizing and responding to DNA damage beyond canonical sequence recognition.

Related Experiment Videos